CORDIS
EU research results

CORDIS

English EN
Intra-operative microscope for tumor margin assessment

Intra-operative microscope for tumor margin assessment

Objective

Breast Cancer is the most common cancer type and main cause of cancer related death in women worldwide. One in eight women in the EU and US will develop breast cancer in their lifetime. Breast-Conserving Surgery (BCS) also called lumpectomy is a standard of care for early breast cancer. Unlike mastectomy, in which the entire breast and lymph nodes are removed, lumpectomy involves only removal of the cancerous tissue and a margin of healthy tissue. Government initiatives to increase public awareness for early breast cancer detection are drastically increasing the number of patients eligible for BCS. Now, BCS is the most performed breast cancer surgery and accounts today for about 70% of all breast cancer surgeries. In counterpart, BCS brings about a risk for the patient to need to undergo an additional surgery in case that not all the cancerous tissue is removed. Re-operation rates (RoR) in BCS are evaluated at 30% on average. Re-operation in BCS is costly for hospitals (€20.000 per re-operation), inconvenient for patients and delays initiation of adjuvant therapies. There is a clinical need for improved intra-operative margin assessment (IMA) methods to assess breast cancer tumor specimen margins in real time in the operating room to decrease RoR. HistologTM Digital Solution allows surgeons real-time, accurate, affordable, whole margin breast tumor assessment through the highest resolution at cellular and subcellular level by using a user-friendly graphical interface supported by a differentiating Automating Reading CAD tool without the need of a pathologist. HistologTM Digital Solution is fully compatible with the gold standard post-operational H&E assessment since it does not destroy specimen and can be integrated with patient information systems. SamanTree Medical’s goal is to make of HistologTM Digital Solution the standard for IMA of breast cancer tumor margins, and decrease the RoR from the current 30% to less than 3%.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

SAMAN TREE MEDICAL SA

Address

Rue De Geneve 88 Bis
1004 Lausanne

Switzerland

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU Contribution

€ 2 317 087,50

Project information

Grant agreement ID: 823284

Status

Ongoing project

  • Start date

    1 September 2018

  • End date

    31 August 2020

Funded under:

H2020-EU.3.

H2020-EU.2.3.

H2020-EU.2.1.

  • Overall budget:

    € 3 310 125

  • EU contribution

    € 2 317 087,50

Coordinated by:

SAMAN TREE MEDICAL SA

Switzerland